Merck and Pfizer Inc. said FDA accepted for priority review the BLAfor avelumab for patients with locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-based therapy.
Bristol-Myers Squibb announced that Columbia University Medical Center and Peter MacCallum Cancer Centre joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between BMS and academia that aims to advance immuno-oncology science and translational medicine to improve patient outcomes.
Exelixis Inc. and Bristol-Myers Squibb Co. entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis' small molecule inhibitor of receptor tyrosine kinases, with BMS's Opdivo (nivolumab), either alone or in combination with Yervoy (ipilimumab).
Exelixis Inc. announced a new collaboration with Roche on a phase Ib dose escalation study that will evaluate the safety and tolerability of cabozantinib, Exelixis' tyrosine kinase inhibitor, in combination with atezolizumab, Roche's anti-PD-L1 immunotherapy, in patients with locally advanced or metastatic solid tumors.
Advaxis Inc. granted SELLAS Life Sciences Group a license to develop a novel cancer immunotherapy agent using Advaxis' proprietary Lm-based antigen delivery technology with SELLAS' patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).
The Karmanos Cancer Institute and Wayne State University School of Medicine will launch the nation's largest study of African American cancer survivors to better understand disproportionately high incidence and mortality from cancer and its impact on this specific patient population.
Sheldon M. Feldman was named chief of the division of breast surgery and surgical oncology, and director of Breast Cancer Services at Montefiore Einstein Center for Cancer Care, the clinical arm of the Albert Einstein Cancer Center.
Michael Rosen was named chief communications officer at the Pancreatic Cancer Action Network.
After three rounds of competition — one of which involved a public vote — a software tool developed by researchers at Fred Hutchinson Cancer Research Center and the University of Basel to track Zika, Ebola and other viral disease outbreaks in real time has won the first-ever international Open Science Prize.
Fred Hutchinson Cancer Research Center today announced the recipients of the Harold M. Weintraub Graduate Student Award, which recognizes the outstanding achievement of graduate studies in the biological sciences. The thirteen award recipients were chosen by a selection committee of Fred Hutch faculty members and students for the quality, originality and significance of their work, and for representation of a diverse range of research topics.
